Eiger BioPharmaceuticals Inc expected to post a loss of 64  cents a share - Earnings Preview

Eiger Biopharmaceuticals

08/03/2022 23:08

* Eiger BioPharmaceuticals Inc  EIGR.OQ   EIGR.O  is
expected
to show a rise in quarterly revenue when it reports  results on
March 10. 
    * The Palo Alto California-based  company is expected to
report
revenue of $3.344 million, according to the mean estimate from 4
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Eiger
BioPharmaceuticals
Inc is for a loss of 64 cents per share. For the same quarter
last year, the company reported a loss of 57 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $25.5​, above​ its last closing price
of $4.27. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.56       -0.56      -0.65     Missed  -15.9
 Jun. 30 2021  -0.54       -0.55      -0.57     Missed  -4.2
 Mar. 31 2021  0.05        -0.02      -0.51     Missed  -2,061
                                                        ​
 Dec. 31 2020  0.14        0.25       -0.57     Missed  -325.4
 ​​Sep.        -0.55       -0.59      -0.52     Beat    11.6
 30 2020                                                
 Jun. 30 2020  -0.70       -0.71      -0.60     Beat    15.9​
 Mar. 31 2020  -0.74       -0.80      -0.62     Beat    22.8
 Dec. 31 2019  -0.77       -0.43      -0.68     Missed  -58
 This summary was machine generated March 8 at 23:08 GMT.  All
figures in US dollars  unless otherwise stated